Not recruitingEUCTR 2020-003745-11
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X)
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
- Listed locations
- Vienna and 87 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 1,401
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Belgium, Austria, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2020-003745-11
- Official title
Show the full official title
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X)
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vienna, Austria · Bertrix, Belgium · Bierbeek, Belgium
78 more locations
- Duffel, Belgium
- Mechelen, Belgium
- Plovdiv, Bulgaria
- Sofiya, Bulgaria
- Grad Zagreb, Croatia
- Rijeka, Croatia
- Zagreb, Croatia
- Klecany, Czechia
- Plzen 3, Czechia
- Poruba, Czechia
- Prague, Czechia
- Ricany, Czechia
- Aalborg, Denmark
- Aarhus N, Denmark
- Glostrup, Denmark
- Espoo, Finland
- Helsinki, Finland
- Turku, Finland
- Bordeaux, France
- Creteil, France
- Montpellier Cedex 5, France
- Nantes, France
- Nice, France
- Nimes Cedex 9, France
- Rouffach, France
- Bad Homburg, Germany
- Berlin, Germany
- Boeblingen, Germany
- Dortmund, Germany
- Mainz, Germany
- Mannheim, Germany
- Munich, Germany
- Tuebingen, Germany
- Westerstede, Germany
- Athens, Greece
- Irakleio, Greece
- Thessaloniki, Greece
- Budapest, Hungary
- Milan, Italy
- Siena, Italy
- Kaunas, Lithuania
- Vilnius, Lithuania
- Ziegzdriu K., Lithuania
- Groningen, Netherlands
- Fredrikstad, Norway
- Loerenskog, Norway
- Belchatów, Poland
- Bialystok, Poland
- Gdańsk, Poland
- Gliwice, Poland
- Lodz, Poland
- Poznań, Poland
- Swiecie, Poland
- Szczecin, Poland
- Warsaw, Poland
- Zabrze, Poland
- Leiria, Portugal
- Lisbon, Portugal
- Loures, Portugal
- Bucharest, Romania
- Sibiu, Romania
- Bojnice, Slovakia
- Kosice - Zapad, Slovakia
- Rimavska Sobota, Slovakia
- Barcelona, Spain
- Cordoba, Spain
- Getafe, Spain
- Madrid, Spain
- Majadahonda, Spain
- Palma, Spain
- Salamanca, Spain
- Sevilla, Spain
- Valencia, Spain
- Vigo, Spain
- Zamora, Spain
- Helsingborg, Sweden
- Uppsala, Sweden
- Czechia
Registry details
Original registry record (opens in a new tab)Current country statuses
- Austria — Ended
- Belgium — Ended
- Bulgaria — Ended
- Croatia — Ended
- Czechia — Ended
- Denmark — Ended
- Finland — Ended
- France — Ended
- Germany — Ended
- Greece — Ended
- Hungary — Ended
- Italy — Ended
- Lithuania — Ended
- Netherlands — Ended
- Norway — Ended
- Poland — Ended
- Portugal — Ended
- Romania — Ended
- Slovakia — Ended
- Spain — Ended
- Sweden — Ended
Historical country statuses
- Austria — Trial now transitioned
- Belgium — Trial now transitioned
- Bulgaria — Trial now transitioned
- Czechia — Trial now transitioned
- Denmark — Trial now transitioned
- Spain — Ongoing
- Finland — Trial now transitioned
- France — Trial now transitioned
- Greece — Trial now transitioned
- Croatia — Trial now transitioned
- Hungary — Trial now transitioned
- Italy — Trial now transitioned
- Lithuania — Trial now transitioned
- Netherlands — Trial now transitioned
- Norway — Trial now transitioned
- Portugal — Trial now transitioned
- Romania — Trial now transitioned
- Sweden — Trial now transitioned
- Slovakia — Trial now transitioned
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Who can participate?
This study is for people with schizophrenia. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...